vs
Aurinia Pharmaceuticals Inc.（AUPH）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
Aurinia Pharmaceuticals Inc.的季度营收约是万物新生的1.8倍（$77.1M vs $43.2M），Aurinia Pharmaceuticals Inc.净利率更高（273.4% vs 16.9%，领先256.5%）
Aurinia Pharmaceuticals是一家生物制药企业，专注于自身免疫疾病及肾脏疾病靶向疗法的研发与商业化，核心获批产品为用于治疗成人活动性狼疮性肾炎的Lupkynis，主要市场覆盖北美及欧洲地区。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
AUPH vs RERE — 直观对比
营收规模更大
AUPH
是对方的1.8倍
$43.2M
净利率更高
AUPH
高出256.5%
16.9%
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $77.1M | $43.2M |
| 净利润 | $210.8M | $7.3M |
| 毛利率 | 88.6% | — |
| 营业利润率 | 43.1% | — |
| 净利率 | 273.4% | 16.9% |
| 营收同比 | 28.8% | — |
| 净利润同比 | 14651.2% | — |
| 每股收益（稀释后） | $1.52 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUPHRERE
| Q4 25 | $77.1M | — | ||
| Q3 25 | $73.5M | — | ||
| Q2 25 | $70.0M | — | ||
| Q1 25 | $62.5M | — | ||
| Q4 24 | $59.9M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $57.2M | — | ||
| Q1 24 | $50.3M | — |
净利润AUPHRERE
| Q4 25 | $210.8M | — | ||
| Q3 25 | $31.6M | — | ||
| Q2 25 | $21.5M | — | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $14.3M | — | ||
| Q2 24 | $722.0K | — | ||
| Q1 24 | $-10.7M | — |
毛利率AUPHRERE
| Q4 25 | 88.6% | — | ||
| Q3 25 | 88.9% | — | ||
| Q2 25 | 89.8% | — | ||
| Q1 25 | 86.3% | — | ||
| Q4 24 | 90.7% | — | ||
| Q3 24 | 91.1% | — | ||
| Q2 24 | 84.4% | — | ||
| Q1 24 | 84.6% | — |
营业利润率AUPHRERE
| Q4 25 | 43.1% | — | ||
| Q3 25 | 40.5% | — | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 35.0% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | 17.3% | — | ||
| Q2 24 | -2.6% | — | ||
| Q1 24 | -26.3% | — |
净利率AUPHRERE
| Q4 25 | 273.4% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 30.7% | — | ||
| Q1 25 | 37.4% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 21.2% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | -21.4% | — |
每股收益（稀释后）AUPHRERE
| Q4 25 | $1.52 | — | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $-0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.2M | $228.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $581.3M | $557.1M |
| 总资产 | $751.6M | $722.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AUPHRERE
| Q4 25 | $80.2M | — | ||
| Q3 25 | $72.9M | — | ||
| Q2 25 | $52.9M | — | ||
| Q1 25 | $66.1M | — | ||
| Q4 24 | $83.4M | — | ||
| Q3 24 | $36.6M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $63.9M | — |
股东权益AUPHRERE
| Q4 25 | $581.3M | — | ||
| Q3 25 | $365.8M | — | ||
| Q2 25 | $335.3M | — | ||
| Q1 25 | $350.2M | — | ||
| Q4 24 | $377.5M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $364.6M | — | ||
| Q1 24 | $359.5M | — |
总资产AUPHRERE
| Q4 25 | $751.6M | — | ||
| Q3 25 | $527.5M | — | ||
| Q2 25 | $502.6M | — | ||
| Q1 25 | $504.9M | — | ||
| Q4 24 | $550.6M | — | ||
| Q3 24 | $549.4M | — | ||
| Q2 24 | $523.5M | — | ||
| Q1 24 | $516.6M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.7M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.22× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AUPHRERE
| Q4 25 | $45.7M | — | ||
| Q3 25 | $44.4M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $30.1M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $15.8M | — | ||
| Q1 24 | $-18.6M | — |
现金转化率AUPHRERE
| Q4 25 | 0.22× | — | ||
| Q3 25 | 1.41× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 21.07× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 21.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
RERE
暂无分部数据
